Physiology of mRNA's Inside Body?

This request has been withdrawn by the person who made it. There may be an explanation in the correspondence below.

Dominique Anderson

Dear Medicines and Healthcare products Regulatory Agency,

I am requesting documents detailing physiology of mRNAs inside of the body? Compared to without?

Yours faithfully,

Dominique Anderson

MHRA Customer Services, Medicines and Healthcare products Regulatory Agency

Thank you for your email.  This auto-response is to inform you that your
email has been received and will be reviewed by our Customer Service Team.
We will respond to you as soon as possible. 

 

Please note that we may not respond if your query: 

 

• contains offensive language
• has already been answered in a previous reply to you
• is illegible
• is selling or promoting a product
• is for information only 

 

Medicines and Healthcare products Regulatory Agency
10 South Colonnade, 
Canary Wharf, 
London 
E14 4PU
gov.uk/mhra
Stay connected 
 
For information on how the Agency uses your personal data and your data
protection rights, please see our three centres’ Privacy Notices: MHRA,
CPRD and NIBSC. 

 

The UK has left the EU, and the transition period ends on 31 December
2020. Our [1]guidance and information can be accessed here. 

References

Visible links
1. https://www.gov.uk/government/collection...

Dominique Anderson

Dear Medicines and Healthcare products Regulatory Agency,

I look forward to you fulfilling my FOI request.

Yours faithfully,

Dominique Anderson

MHRA Customer Services, Medicines and Healthcare products Regulatory Agency

Our Ref: FOI 21/152

Dear Dominique Anderson,

RE: REQUEST UNDER THE FREEDOM OF INFORMATION ACT 2000

Thank you for your enquiry which we received on 20 January 2021.

I confirm that your request is now being handled under the Freedom of Information Act and you should receive a reply within 20 working days from our date of receipt.

If you need to contact us again about this request, please quote the reference number above.

Kind Regards,


MHRA Customer Service Centre

Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU

show quoted sections

MHRA Customer Services, Medicines and Healthcare products Regulatory Agency

19 Attachments

  • Attachment

    FOI 21 152 Freedom of Information request Isolation of variant SARS CoV 2 D614G.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request SARS CoV 2 Coronavirus Antibodies Compared with Natural Immunoglobulin Antibodies.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Isolation of SARS CoV 2 Cluster 5 variant.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Isolation of SARS CoV 2 VOC 202012 01.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Isolation of SARS CoV 2 N501Y mutation.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Isolation of SARS CoV 2 501Y.V2 variants.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Isolation of Spanish SARS CoV 2 variant A222V.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Isolation of New UK Coronavirus variant.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Biotechnology Johnson Johnson s mRNA Risk Assessment vs a Healthy Immune System Part 2.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Biotechnology Johnson Johnson s mRNA Risk Assessment vs a Healthy Immune System Part 1.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Johnson Johnson s mRNA Very Encouraging Trial Results.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Biotechnology Noravax mRNA Risk Assessment vs a Healthy Immune System Part 1.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Re Freedom of Information request Biotechnology Noravax mRNA Risk Assessment vs a Healthy Immune System Part 1.txt

    3K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Biotechnology Noravax mRNA Risk Assessment vs a Healthy Immune System Part 2.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Biotechnology Valneva VLA2001 mRNA Risk Assessment vs a Healthy Immune system.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Biotechnology GlaxoSmithKline mRNA Risk Assessment vs a Healthy Immune system Part1.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Biotechnology GlaxoSmithKline mRNA Risk Assessment vs a Healthy Immune system Part 2.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Biotechnology Valneva VLA2001 mRNA Risk Assessment and the Immune system.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Isolation of the new Coronavirus Variant found in Bristol..txt

    2K Download View as HTML

FOI 21/152

Dear Dominique Anderson,

Thank you for your emails below and attached.

Regarding the effects of mRNA vaccines on the body, the effects can be seen through the clinical trials that have been performed on all three authorised vaccines. Details of these trials can be found in our previous response to you, dated 3 February 2021.

Regarding your enquiries on variants of the COVID-19 virus strains, MHRA holds no information on the isolation of variants.

Regarding your enquiries concerning vaccines that have no marketing authorisation granted by MHRA, MHRA neither confirms nor denies that it holds information falling within the description specified in your request. The duty in Section 1(1)(a) of the Freedom of Information (FOI) Act 2000 does not apply, by virtue of Section 41 (Information provided in confidence) and Section 43 (Commercial interests) of that Act. This should not be taken as an indication that the information you requested is or is not held by the department.

Section 41 is an absolute exemption and no consideration of the public interest is required, except to state that we consider the disclosure of such information to constitute an actionable breach of confidence.

Section 43 is a qualified exemption and a consideration of the public interest should be made. We have considered the public interest and cannot see any public interest argument that outweighs the commercial harm in publishing this information, which can be used by competitors for their commercial gain. Examples of public interest arguments would be a major public health risk or a major procedural failure or irregularity.

If you disagree with how we have interpreted the Freedom of Information Act 2000 with regards to your request, you can ask for the decision to be reviewed. The review will be carried out by a senior member of the Agency who was not involved with the original decision.

If you have a query about the information provided, please reply to this email

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date you receive this response and addressed to: [MHRA request email]

Due to the ongoing Covid-19 situation, we are not able to accept delivery of any documents or correspondence by post or courier to any of our offices

Please remember to quote the reference number above in any future communications.

If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:

Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Yours sincerely


MHRA Customer Service Centre

Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU Telephone 0203 080 6000

show quoted sections

MHRA Customer Services, Medicines and Healthcare products Regulatory Agency

20 Attachments

  • Attachment

    FOI 21 152 Freedom of Information request Isolation of variant SARS CoV 2 D614G.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request SARS CoV 2 Coronavirus Antibodies Compared with Natural Immunoglobulin Antibodies.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Isolation of SARS CoV 2 Cluster 5 variant.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Isolation of SARS CoV 2 VOC 202012 01.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Isolation of SARS CoV 2 N501Y mutation.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Isolation of SARS CoV 2 501Y.V2 variants.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Isolation of Spanish SARS CoV 2 variant A222V.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Isolation of New UK Coronavirus variant.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Biotechnology Johnson Johnson s mRNA Risk Assessment vs a Healthy Immune System Part 2.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Biotechnology Johnson Johnson s mRNA Risk Assessment vs a Healthy Immune System Part 1.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Johnson Johnson s mRNA Very Encouraging Trial Results.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Biotechnology Noravax mRNA Risk Assessment vs a Healthy Immune System Part 1.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Re Freedom of Information request Biotechnology Noravax mRNA Risk Assessment vs a Healthy Immune System Part 1.txt

    3K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Biotechnology Noravax mRNA Risk Assessment vs a Healthy Immune System Part 2.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Biotechnology Valneva VLA2001 mRNA Risk Assessment vs a Healthy Immune system.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Biotechnology GlaxoSmithKline mRNA Risk Assessment vs a Healthy Immune system Part1.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Biotechnology GlaxoSmithKline mRNA Risk Assessment vs a Healthy Immune system Part 2.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Biotechnology Valneva VLA2001 mRNA Risk Assessment and the Immune system.txt

    2K Download View as HTML

  • Attachment

    FOI 21 152 Freedom of Information request Isolation of the new Coronavirus Variant found in Bristol..txt

    2K Download View as HTML

  • Attachment

    FOI 21 048 Freedom of Information request Biotechnology Risk Assessment Oxford AstraZeneca ChAdOx1 nCoV 19 AZD1222 mRNA vs a Healthy Immune system.txt

    3K Download View as HTML

FOI 21/152

Dear Dominique Anderson,

Thank you for your emails below and attached.

Regarding the effects of mRNA vaccines on the body, the effects can be seen through the clinical trials that have been performed on all three authorised vaccines. Details of these trials can be found in our previous response to you, dated 3 February 2021.

Regarding your enquiries on variants of the COVID-19 virus strains, MHRA holds no information on the isolation of variants.

Regarding your enquiries concerning vaccines that have no marketing authorisation granted by MHRA, MHRA neither confirms nor denies that it holds information falling within the description specified in your request. The duty in Section 1(1)(a) of the Freedom of Information (FOI) Act 2000 does not apply, by virtue of Section 41 (Information provided in confidence) and Section 43 (Commercial interests) of that Act. This should not be taken as an indication that the information you requested is or is not held by the department.

Section 41 is an absolute exemption and no consideration of the public interest is required, except to state that we consider the disclosure of such information to constitute an actionable breach of confidence.

Section 43 is a qualified exemption and a consideration of the public interest should be made. We have considered the public interest and cannot see any public interest argument that outweighs the commercial harm in publishing this information, which can be used by competitors for their commercial gain. Examples of public interest arguments would be a major public health risk or a major procedural failure or irregularity.

If you disagree with how we have interpreted the Freedom of Information Act 2000 with regards to your request, you can ask for the decision to be reviewed. The review will be carried out by a senior member of the Agency who was not involved with the original decision.

If you have a query about the information provided, please reply to this email

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date you receive this response and addressed to: [MHRA request email]

Due to the ongoing Covid-19 situation, we are not able to accept delivery of any documents or correspondence by post or courier to any of our offices

Please remember to quote the reference number above in any future communications.

If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:

Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Yours sincerely


MHRA Customer Service Centre

Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU Telephone 0203 080 6000

show quoted sections

Dominique Anderson

Dear MHRA Customer Services,

Can you please direct me to who I need to contact to prove that Sars cov 2 has been isolated? Obviously, somebody will have the information or not I have asked for to justify all of the commotions with lockdowns, social distancing and wearing face coverings. I am surprised you are not jumping in to quickly reassure the public Sars Cov-2 virus exists with solid proof. I asked for specific information to prove the claim to the public.

Yours sincerely,

Dominique Anderson